Literature DB >> 22702513

Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity.

Bhaskar Reddy Kusuma1, Liang Zhang, Teather Sundstrom, Laura B Peterson, Rick T Dobrowsky, Brian S J Blagg.   

Abstract

Compound 2 (KU-32) is a first-generation novologue (a novobiocin-based, C-terminal, heat shock protein 90 (Hsp90) inhibitor) that decreases glucose-induced death of primary sensory neurons and reverses numerous clinical indices of diabetic peripheral neuropathy in mice. The current study sought to exploit the C-terminal binding site of Hsp90 to determine whether the optimization of hydrogen bonding and hydrophobic interactions of second-generation novologues could enhance neuroprotective activity. Using a series of substituted phenylboronic acids to replace the coumarin lactone of 2, we identified that electronegative atoms placed at the meta-position of the B-ring exhibit improved cytoprotective activity, which is believed to result from favorable interactions with Lys539 in the Hsp90 C-terminal binding pocket. Consistent with these results, a meta-3-fluorophenyl substituted novologue (13b) exhibited a 14-fold lower ED(50) for protection against glucose-induced toxicity of primary sensory neurons compared to 2.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22702513      PMCID: PMC3390240          DOI: 10.1021/jm300544c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  24 in total

Review 1.  Modulation of neurodegeneration by molecular chaperones.

Authors:  Paul J Muchowski; Jennifer L Wacker
Journal:  Nat Rev Neurosci       Date:  2005-01       Impact factor: 34.870

2.  Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.

Authors:  Joseph A Burlison; Christopher Avila; George Vielhauer; Donna J Lubbers; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  J Org Chem       Date:  2008-02-23       Impact factor: 4.354

3.  Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Authors:  Zhonghua Pei; Xiaofeng Li; Thomas W von Geldern; David J Madar; Kenton Longenecker; Hong Yong; Thomas H Lubben; Kent D Stewart; Bradley A Zinker; Bradley J Backes; Andrew S Judd; Mathew Mulhern; Stephen J Ballaron; Michael A Stashko; Amanda K Mika; David W A Beno; Glenn A Reinhart; Ryan M Fryer; Lee C Preusser; Anita J Kempf-Grote; Hing L Sham; James M Trevillyan
Journal:  J Med Chem       Date:  2006-11-02       Impact factor: 7.446

4.  C-terminal heat shock protein 90 inhibitor decreases hyperglycemia-induced oxidative stress and improves mitochondrial bioenergetics in sensory neurons.

Authors:  Liang Zhang; Huiping Zhao; Brian S J Blagg; Rick T Dobrowsky
Journal:  J Proteome Res       Date:  2012-03-28       Impact factor: 4.466

5.  Cell culture modeling to test therapies against hyperglycemia-mediated oxidative stress and injury.

Authors:  Andrea M Vincent; Martin J Stevens; Carey Backus; Lisa L McLean; Eva L Feldman
Journal:  Antioxid Redox Signal       Date:  2005 Nov-Dec       Impact factor: 8.401

Review 6.  Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options.

Authors:  Aristidis Veves; Miroslav Backonja; Rayaz A Malik
Journal:  Pain Med       Date:  2008-09       Impact factor: 3.750

7.  Molecular design of potent tyrosinase inhibitors having the bibenzyl skeleton.

Authors:  Hiromi Oozeki; Reiko Tajima; Ken-ichi Nihei
Journal:  Bioorg Med Chem Lett       Date:  2008-08-22       Impact factor: 2.823

Review 8.  Glucose neurotoxicity.

Authors:  David R Tomlinson; Natalie J Gardiner
Journal:  Nat Rev Neurosci       Date:  2008-01       Impact factor: 34.870

9.  Immortalization and characterization of a nociceptive dorsal root ganglion sensory neuronal line.

Authors:  Weiran Chen; Ruifa Mi; Norman Haughey; Murat Oz; Ahmet Höke
Journal:  J Peripher Nerv Syst       Date:  2007-06       Impact factor: 3.494

10.  Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90.

Authors:  Joseph A Burlison; Len Neckers; Andrew B Smith; Anthony Maxwell; Brian S J Blagg
Journal:  J Am Chem Soc       Date:  2006-12-06       Impact factor: 15.419

View more
  23 in total

1.  Trifunctional High-Throughput Screen Identifies Promising Scaffold To Inhibit Grp94 and Treat Myocilin-Associated Glaucoma.

Authors:  Dustin J E Huard; Vincent M Crowley; Yuhong Du; Ricardo A Cordova; Zheying Sun; Moya O Tomlin; Chad A Dickey; John Koren; Laura Blair; Haian Fu; Brian S J Blagg; Raquel L Lieberman
Journal:  ACS Chem Biol       Date:  2018-02-20       Impact factor: 5.100

2.  Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.

Authors:  Huiping Zhao; Mercy Anyika; Antwan Girgis; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2014-05-16       Impact factor: 2.823

3.  Development of radamide analogs as Grp94 inhibitors.

Authors:  Aaron Muth; Vincent Crowley; Anuj Khandelwal; Sanket Mishra; Jinbo Zhao; Jessica Hall; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2014-06-12       Impact factor: 3.641

4.  Management of Hsp90-Dependent Protein Folding by Small Molecules Targeting the Aha1 Co-Chaperone.

Authors:  Jay K Singh; Darren M Hutt; Bradley Tait; Naihsuan C Guy; Jeffrey C Sivils; Nina R Ortiz; Ashley N Payan; Shravan Kumar Komaragiri; Jazzmin Jovonna Owens; David Culbertson; Laura J Blair; Chad Dickey; Szu Yu Kuo; Dan Finley; H Jane Dyson; Marc B Cox; Jaideep Chaudhary; Jason E Gestwicki; William E Balch
Journal:  Cell Chem Biol       Date:  2020-02-03       Impact factor: 8.116

5.  Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer.

Authors:  Leah K Forsberg; Weiya Liu; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2017-07-11       Impact factor: 2.823

6.  Targeting Heat Shock Protein 70 to Ameliorate c-Jun Expression and Improve Demyelinating Neuropathy.

Authors:  Xinyue Zhang; Chengyuan Li; Stephen C Fowler; Zheng Zhang; Brian S J Blagg; Rick T Dobrowsky
Journal:  ACS Chem Neurosci       Date:  2017-11-09       Impact factor: 4.418

7.  Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects.

Authors:  Leah K Forsberg; Mercy Anyika; Zhenyuan You; Sean Emery; Mason McMullen; Rick T Dobrowsky; Brian S J Blagg
Journal:  Eur J Med Chem       Date:  2017-10-18       Impact factor: 6.514

8.  Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity.

Authors:  Zheng Zhang; Zhenyuan You; Rick T Dobrowsky; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2018-03-26       Impact factor: 2.823

Review 9.  Promoting Neuronal Tolerance of Diabetic Stress: Modulating Molecular Chaperones.

Authors:  S M Emery; R T Dobrowsky
Journal:  Int Rev Neurobiol       Date:  2016-04-05       Impact factor: 3.230

10.  Novobiocin Analogues That Inhibit the MAPK Pathway.

Authors:  Jessica A Hall; Sahithi Seedarala; Huiping Zhao; Gaurav Garg; Suman Ghosh; Brian S J Blagg
Journal:  J Med Chem       Date:  2016-01-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.